Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 10/20 | 0.47 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.45 |
| ▸ | GPR39 | O43194 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3500158 | 0.88 | JAK2 (0.62) | CHEK1JAK2ACVR1GPR39KCNH2 | |
| SCHEMBL3501401 | 0.84 | JAK2 (0.49) | CHEK1JAK2ACVR1GPR39KCNH2 | |
| SCHEMBL3502426 | 0.81 | JAK2 (0.61) | CHEK1JAK2ACVR1PRMT5WDR77 | |
| SCHEMBL2874886 | 0.76 | JAK2 (0.66) | CHEK1JAK2ACVR1LRRK2PIK3CA | |
| SCHEMBL3503329 | 0.76 | JAK2 (0.66) | CHEK1JAK2ACVR1LRRK2PIK3CA | |
| SCHEMBL3502471 | 0.76 | JAK2 (0.66) | CHEK1JAK2ACVR1LRRK2PIK3CA | |
| SCHEMBL2461060 | 0.76 | JAK2 (0.65) | CHEK1JAK2ACVR1KCNH2PRMT5 | |
| SCHEMBL2876498 | 0.73 | JAK2 (0.65) | CHEK1JAK2ACVR1KCNH2 | |
| SCHEMBL3501381 | 0.73 | JAK2 (0.66) | CHEK1JAK2ACVR1 | |
| SCHEMBL2458102 | 0.71 | CHEK1 (0.55) | CHEK1JAK2ACVR1KCNH2PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197634-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197634-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | CHEK1 740/4885JAK2 1/4885ACVR1 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.